DexCom (DXCM) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2521311074
DexCom, Inc. is a leading medical device company that specializes in creating and selling continuous glucose monitoring (CGM) systems worldwide. These systems are mainly used by individuals with diabetes and healthcare professionals to monitor glucose levels constantly.
The company offers innovative products like Dexcom G6 and Dexcom G7, which are advanced integrated CGM systems tailored for efficient diabetes management. Additionally, DexCom provides solutions such as Dexcom Share for remote monitoring and Dexcom Real-Time API for seamless integration into digital health apps and devices from third-party developers.
One noteworthy product from DexCom is Dexcom ONE, which is engineered to eliminate the need for traditional finger stick blood glucose testing, making diabetes treatment decisions smoother and more accurate. On a significant note, DexCom has a pending FDA review for Dexcom Stelo, a system designed specifically for individuals with type 2 diabetes.
Furthermore, DexCom has strategic collaborations with Verily Life Sciences LLC and Verily Ireland Limited to develop cutting-edge blood-based or interstitial glucose monitoring products. The company primarily markets its products directly to endocrinologists, physicians, and diabetes educators for widespread use and accessibility.
Founded in 1999 and headquartered in San Diego, California, DexCom continues to drive innovation and set new standards in the field of continuous glucose monitoring. For more information, visit their website at https://www.dexcom.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
DXCM Stock Overview
Market Cap in USD | 51,366m |
Sector | Healthcare |
Industry | Medical Devices |
GiC SubIndustry | Health Care Equipment |
TER | 0.00% |
IPO / Inception | 2005-04-14 |
DXCM Stock Ratings
Fundamental | 7.32 |
Dividend | - |
Growth 5y | 6.74 |
Rel. Performance vs Sector | 0.34 |
Analysts | 4.61/5 |
Fair Price Momentum | 144.36 USD |
Fair Price DCF | 36.08 USD |
DXCM Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
DXCM Growth Ratios
Growth 12m | 22.39% |
Growth Correlation 12m | 8% |
Growth Correlation 3m | 13% |
CAGR 5y | 37.03% |
Sharpe Ratio 12m | 0.44 |
Alpha vs SP500 12m | -14.30 |
Beta vs SP500 5y weekly | 1.16 |
ValueRay RSI | 84.24 |
Volatility GJR Garch 1y | 39.99% |
Price / SMA 50 | 11.16% |
Price / SMA 200 | 22.08% |
Current Volume | 2031.8k |
Average Volume 20d | 3450.2k |
External Links for DXCM Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 29, 2024, the stock is trading at USD 139.48 with a total of 2,031,775 shares traded.
Over the past week, the price has changed by +5.24%, over one month by +20.95%, over three months by +12.73% and over the past year by +20.17%.
According to ValueRays Forecast Model, DXCM DexCom will be worth about 161 in March 2025. The stock is currently trading at 139.48. This means that the stock has a potential upside of +15.46%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 148.4 | 6.38% |
Analysts Target Price | 137 | -1.78% |
ValueRay Target Price | 161 | 15.5% |